Table 4.
Liver Volume Hyperplasia under Different Pathological Types
| TACE + PVE group (n = 11) |
PALPP group (n = 16) |
|||||
|---|---|---|---|---|---|---|
| HCC (n = 11) |
ICC (n = 0) |
MLC (n = 0) |
HCC (n = 12) |
ICCa (n = 2) |
MLCa (n = 2) |
|
| SLV (ml) (median [IQR]) | 1147.9 (1068.6, 1251.5) | NA | NA | 1178.9 (1128.4, 1241.7) | (1232.7, 1268.6) | (1139.2, 1170.3) |
| Liver volume growth time (day) (median [IQR]) | 66 (41.0, 118.0) | NA | NA | 19 (14.3, 40.8) | (11.0, 15.0) | (12.0, 15.0) |
| FLR1 (ml) (median [IQR]) | 383.3 (339.5, 447.0) | NA | NA | 257.2 (199.8, 365.1) | (353.7, 367.4) | (367.4, 372.7) |
| FLR2 (ml) (median [IQR]) | 502.2 (400.0, 586.8) | NA | NA | 523.4 (400.7, 576.7) | (508.5, 518.0) | (540.0, 558.5) |
| FLR3 (ml) (median [IQR]) | 83.1 (43.9, 182.8) | NA | NA | 157.1 (89.3, 212.6) | (146.4, 150.6) | (162.0, 185.8) |
| FLR † (%) (median [IQR]) | 23 (12.0,47.0) | NA | NA | 39.1(26.9, 78.7) | (38.4, 41.1) | (42.9, 49.9) |
| KGR (ml/w) (median [IQR]) | 7.7 (3.2, 33.7) | NA | NA | 40.1(19.6, 107.8) | (54.0, 76.2) | (20.7, 92.6) |
HCC hepatocellular carcinoma, ICC Cholangiocarcinoma, MLC Metastatic liver cancer, SLV standard liver volume; Liver volume growth time, The waiting time between procedures or the time span from phase I surgery to treatment failure, FLR1 First pre-operative FLR, FLR2 FLR before second surgery or FLR at the time of treatment failure, FLR3 FLR3 = FLR2-FLR1; FLR †, The increase in FLR between the two procedures was divided by the FLR before the first procedure (FLR † = FLR3/ FLR1); KGR, Degree of liver volume increase (%)/time elapsed from baseline to final volume before stage II hepatectomy (weeks)
aThe column representation method is (minimum, maximum)